<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04134832</url>
  </required_header>
  <id_info>
    <org_study_id>7435</org_study_id>
    <nct_id>NCT04134832</nct_id>
  </id_info>
  <brief_title>Study of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region</brief_title>
  <official_title>Clinicopathological Assessment of Pancreatic Neuroendocrine Tumors and Carcinomas in Alsace Region</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic Neuroendocrine tumors and carcinomas (pNET) see the last year their incidence and
      prevalence going up. On the basis of their grade of differentiation and proliferation ratio
      measured Ki67 staining, there are divided into 3 grade groups : Grade 1 with Ki67 between 1
      and 3%, Grade 2 between 3 and 20% and well-differentiated neuroendocrine grade tumors 3 with
      KI67 greater than 20%, so undifferentiated carcinomas.

      pNET is a heterogenous group of tumors with variable prognosis. The aim of this study is to
      identify the prognostic factors in this population, as well the place of
      neutrophil-to-lymphocyte ratio as a prognostic marker. The primary endpoint is the
      description of clinic and pathological parameters of patients from Alsace. The secondary
      endpoints are the identification of prognostic factors in this population
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2019</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The survival will be evaluated by Kaplan Meier Method. The prognostic factors will be evaluated with univariate and multivariate analysis by Cox regression model.</measure>
    <time_frame>The participant will be followed-up for a maximum of 11 years, and 1 year at least.</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Pancreatic Neuroendocrine Tumor</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma, with
        tumours or neuroendocrine carcinoma of the pancreas at any stage of the disease and covered
        in one of the participating centres between 01/01/2008 and 01/01/2019
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Major topic ((≥18 years)

          2. Subject with histologically confirmed pancreatic neuroendocrine tumor or carcinoma

          3. Subject with tumours or neuroendocrine carcinoma of the pancreas at any stage of the
             disease.

          4. Subject covered in one of the participating centres between 01/01/2008 and 01/01/2019

          5. Have a pre-therapeutic biological check-up

          6. Subject who has not expressed opposition to the use of his or her data for research
             purposes

        Exclusion criteria:

          1. Subject who expressed opposition to participate in the study

          2. Lack of histological data

          3. Minor subject

          4. Patient under the protection of justice

          5. Subject under guardianship or trusteeship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gabriel MALOUF, MD, PhD</last_name>
    <phone>33 3 88 11 62 22</phone>
    <email>gabriel.malouf@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service D'Hematologie Et D'Oncologie</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel MALOUF, MD, PhD</last_name>
      <phone>33 3 88 11 62 22</phone>
      <email>gabriel.malouf@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Gabriel MALOUF, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marc Limacher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel Achille</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louis-Marie Dourthe</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernard Willemin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphanie Husson</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Meher Ben Abdelghani</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique Debien</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>October 18, 2019</last_update_submitted>
  <last_update_submitted_qc>October 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic neuroendocrine tumors</keyword>
  <keyword>Neutrophil-to-lymphocyte ratio</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Adenoma, Islet Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

